Stock listing

OTC:INTI Inhibitor Therapeutics Inc. Stock

Follow Inhibitor Therapeutics Inc. into a list and get an email when it puts out news.

Share price · OTC:INTI

$0.08 USD +0.00 (+1.3%)

Close on Nov 10, 2026

Past year +50.9% · daily closes, Nov 10, 2025 – Nov 10, 2026, adjusted for splits
Day range
$0.08 – $0.08 USDNov 10, 2026
Volume
80,000 sharesNov 10, 2026
Market cap
$13.98M USDAt the close on Nov 10, 2026 · price × 174.8M shares outstanding
52-week range
$0.04 – $0.124 USDLowest and highest trades, Nov 11, 2025 – Nov 10, 2026
Traded on an average day
$348 USDMedian day 0 shares · 34 days with no trades · last 3 months, Aug 10, 2026 – Nov 10, 2026
Inhibitor Therapeutics Inc. logo

Daily closes

Last 3 months, Aug 10, 2026 – Nov 10, 2026 · OTC:INTI · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.08+0.001+1.3%$0.08$0.08$0.0880,000
$0.0790.000.0%$0.079$0.079$0.0790
$0.0790.000.0%$0.079$0.079$0.0790
$0.0790.000.0%$0.079$0.079$0.0790
$0.079-0.018-18.6%$0.059$0.079$0.0591,500
$0.0970.000.0%$0.097$0.097$0.0970
$0.097+0.032+49.2%$0.097$0.097$0.0972,000
$0.065-0.015-18.8%$0.065$0.065$0.0651,000
$0.080.000.0%$0.08$0.08$0.080
$0.08+0.019+31.1%$0.076$0.08$0.0768,200
$0.061-0.01-14.1%$0.098$0.098$0.061147,700
$0.071-0.018-20.2%$0.071$0.071$0.071100
$0.089+0.001+1.1%$0.08$0.089$0.081,500
$0.088-0.022-20.0%$0.059$0.089$0.0592,200
$0.110.000.0%$0.11$0.11$0.110
$0.110.000.0%$0.11$0.11$0.110
$0.11+0.012+12.2%$0.069$0.11$0.0613,900
$0.0980.000.0%$0.098$0.098$0.0980
$0.098+0.019+24.1%$0.071$0.098$0.05935,900
$0.079+0.02+33.9%$0.079$0.079$0.079500
$0.059-0.039-39.8%$0.059$0.059$0.0595,000
$0.0980.000.0%$0.098$0.098$0.0980
$0.0980.000.0%$0.098$0.098$0.0980
$0.0980.000.0%$0.098$0.098$0.0980
$0.0980.000.0%$0.098$0.098$0.0980
$0.0980.000.0%$0.098$0.098$0.0980
$0.098-0.002-2.0%$0.098$0.098$0.0984,500
$0.100.000.0%$0.10$0.10$0.100
$0.100.000.0%$0.10$0.10$0.100
$0.100.000.0%$0.10$0.10$0.100
$0.100.000.0%$0.10$0.10$0.101,000
$0.100.000.0%$0.10$0.10$0.100
$0.100.000.0%$0.10$0.10$0.100
$0.10+0.041+69.5%$0.10$0.10$0.10300
$0.059-0.03-33.7%$0.06$0.06$0.0591,200
$0.0890.000.0%$0.089$0.089$0.0890
$0.0890.000.0%$0.089$0.089$0.0890
$0.0890.000.0%$0.089$0.089$0.089250
$0.089-0.011-11.0%$0.06$0.089$0.06500
$0.100.000.0%$0.10$0.10$0.10100
$0.100.000.0%$0.10$0.10$0.100
$0.10+0.013+14.9%$0.059$0.10$0.059800
$0.0870.000.0%$0.087$0.087$0.0870
$0.087+0.013+17.6%$0.089$0.089$0.0871,200
$0.0740.000.0%$0.074$0.074$0.0740
$0.0740.000.0%$0.074$0.074$0.0740
$0.074-0.015-16.9%$0.059$0.074$0.0591,200
$0.089+0.021+30.9%$0.089$0.089$0.0891,000
$0.068-0.021-23.6%$0.068$0.068$0.068200
$0.0890.000.0%$0.089$0.089$0.089775
$0.0890.000.0%$0.089$0.089$0.0890
$0.0890.000.0%$0.089$0.089$0.089500
$0.0890.000.0%$0.089$0.089$0.0890
$0.0890.000.0%$0.089$0.089$0.0890
$0.0890.000.0%$0.089$0.089$0.0890
$0.0890.000.0%$0.089$0.089$0.0890
$0.0890.000.0%$0.089$0.089$0.0890
$0.0890.000.0%$0.089$0.089$0.089200
$0.0890.000.0%$0.089$0.089$0.0890
$0.089+0.007+8.5%$0.09$0.09$0.0742,300
$0.0820.000.0%$0.082$0.082$0.0820
$0.0820.000.0%$0.082$0.082$0.0820
$0.082+0.00+0.4%$0.082$0.082$0.0820
$0.082+0.007+8.9%$0.059$0.082$0.0591,275
$0.075+0.016+27.1%$0.075$0.075$0.075500
Ticker
OTC:INTI
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
OTC
Currency
USD

Inhibitor Therapeutics Inc. on 6ix

Sector
Health care
Industry
Biotechnology
Decks
2 decks · latest March 2024

Valuation

Statements: 4 quarters to Sep 30, 2026 · price Nov 10, 2026

Enterprise value
$13.87M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
Negative equity
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
Negative equity
Beta vs S&P 500
-0.61

Biotechnology: the 10 companies nearest in size, of 891 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Inhibitor Therapeutics Inc. · OTC:INTIUS$13.98MUS$13.87Mn/an/an/an/an/an/a-0.61
Vectorite Biomedical, Inc. · TPEX:4170US$14.21MUS$9.16M4.9×4.9×n/a0.9×156.6%0.0×n/a
Estrella Immunopharma, Inc. · NASDAQ:ESLAUS$14.11MUS$14.01Mn/an/an/an/an/an/a1.31
Citius Pharmaceuticals, Inc. · NASDAQ:CTXRUS$13.96M−US$3.05Mn/an/an/a0.2×n/a0.0×1.71
TaiwanJ Pharmaceuticals Co., Ltd. · TPEX:6549US$13.69MUS$11.86Mn/an/an/a7.0×n/a0.0×n/a
Actuate Therapeutics, Inc. · NASDAQ:ACTUUS$13.60MUS$11.50Mn/an/an/an/an/an/a1.75
BeyondSpring, Inc. · NASDAQ:BYSIUS$13.57MUS$12.99M0.3×n/an/a0.9×n/a0.0×1.31
Acumen Pharmaceuticals, Inc. · NASDAQ:ABOSUS$13.49M−US$38.84Mn/an/an/a0.4×n/a0.8×1.45
Pharma Equity Group A/S Class A · OMXCOP:PEGUS$13.48MUS$15.06Mn/an/a52.7×3.6×n/a0.4×n/a
BioInvent International AB · OMXSTO:BINVUS$13.46M−US$6.63Mn/a−1.7×n/a0.7×n/a0.1×n/a
Thalia Therapeutics PLC · LSE:THATUS$13.37MUS$11.40Mn/a1,199×n/a4.2×n/a0.0×n/a
Median of the othersUS$13.59MUS$11.45M2.6×4.9×52.7×0.9×156.6%0.0×1.45

Team and board

Officers

OfficerRole
Niraj VasishtCEO
Michelle YanezChief Financial Officer
Mike JermanCFO
Francis E. O’DonnellFounder/ Executive Officer/ Director

Board

DirectorRole
Ronald E. OsmanChairman of the Board
Samuel SearsManaging Partner, Chairman of the Corporate Department
Francis E. O’DonnellFounder/ Executive Officer/ Director
Michelle YanezChief Financial Officer
Niraj VasishtCEO

Events

QuarterResultsShare move
Q3 2025Nov 13, 20250.0%
Q2 2025Aug 13, 2025−20.4%
Q1 2025May 12, 2025 · Before open−21.4%
Q4 2024Mar 27, 2025 · After close−3.3%
Q3 2024Nov 11, 2024 · Before open−2.3%
Q2 2024Aug 6, 2024 · Before open0.0%
Q1 2024May 13, 2024 · Before open+14.1%
Q4 2023Mar 29, 2024 · After close−2.9%
Q3 2023Nov 13, 2023 · Before open−42.3%
Q2 2023Aug 11, 2023 · Before open−4.5%
All 20 quarters
QuarterResultsShare move
Q1 2023May 15, 2023 · Before open0.0%
Q4 2022Mar 31, 2023 · After close+25.0%
Q3 2022Nov 14, 2022 · After close+1.7%
Q2 2022Aug 15, 20220.0%
Q1 2022May 12, 2022+4.3%
Q4 2021Feb 24, 20220.0%
Quarter to Sep 30, 2021Nov 16, 20210.0%
Quarter to Jun 30, 2021Aug 16, 2021−7.5%
Quarter to Mar 31, 2021May 13, 2021−2.7%
Quarter to Dec 31, 2020Feb 25, 2021−27.7%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (March 2024)Investor deck29 slidesMarch 2024
Investor Presentation (August 2019)Investor deck21 slidesAug 20, 2019

Open Decks

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue000000
Research and development1.70M1.76M1.38M6.15K4.91K185.3K1.21M2.63M2.23M2.64M
Operating income-3.43M-3.66M-3.40M-657.9K-325.4K-1.06M-2.75M-4.56M-5.12M-7.02M
Interest expense23.2K14.8K
Income before tax-3.03M12.2M-298.6K
Income tax55.1K000000
Net income-3.30M-3.34M-3.03M12.1M-298.6K-1.06M-2.73M-4.55M-5.10M-7.00M
Earnings per share, basic-0.02-0.02-0.020.030.000.00-0.01-0.01-0.01-0.02
Earnings per share, diluted-0.02-0.02-0.020.030.000.00-0.01-0.01-0.01-0.02

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents2.38M5.61M8.84M12.0M30.6K75.1K803.8K1.11M344.1K6.89M
Current assets2.45M5.69M8.95M12.0M58.8K107.4K846.3K1.15M655.8K7.20M
Total assets2.51M5.69M8.95M12.0M58.8K131.8K900.0K1.23M768.1K7.34M
Accounts payable51.5K15.9K33.7K145.2K279.8K269.4K315.9K384.8K535.0K297.8K
Current liabilities766.3K709.6K665.2K678.8K679.6K425.4K431.1K700.6K601.5K308.1K
Long-term debt36.9K
Total debt24.7K
Total liabilities3.80M3.71M3.67M3.68M3.68M3.49M3.43M1.20M601.5K308.1K
Shareholders' equity-1.29M1.99M5.28M8.30M-3.62M-3.36M-2.53M32.4K166.6K7.03M
Shares outstanding172.6M172.3M172.0M171.8M376.9M373.6M370.4M370.1M369.6M353.4M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-3.23M-3.23M-2.70M11.7M-220.4K-825.4K-2.71M-3.71M-2.91M-3.76M
Cash from financing-411.0K180.0K176.0K96.6K2.40M4.47M-3.63M10.0M
Dividends paid0-99.2K
Change in cash-3.23M-3.23M-3.11M11.9M-44.4K-728.8K-304.9K764.6K-6.54M6.28M

Open Financials

Filings

FilingDateTypeFiled with
10-Q · Quarterly reportNov 16, 2026Quarterly reportSEC
8-K · Current reportSep 18, 2026Management or board changeSEC
DEF 14A · Proxy statementAug 17, 2026Meeting noticeSEC
10-Q · Quarterly reportAug 14, 2026Quarterly reportSEC
4 · Change in ownershipAug 4, 2026Insider tradeSEC
4 · Change in ownershipAug 4, 2026Insider tradeSEC
4 · Change in ownershipAug 4, 2026Insider tradeSEC
4 · Change in ownershipAug 4, 2026Insider tradeSEC
4 · Change in ownershipAug 4, 2026Insider tradeSEC
4 · Change in ownershipJun 24, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
4 · Change in ownershipJun 1, 2026Insider tradeSEC
10-Q · Quarterly reportMay 15, 2026Quarterly reportSEC
8-K · Current reportApr 1, 2026Current reportSEC
8-K · Current reportApr 1, 2026Current reportSEC
10-K · Annual reportMar 25, 2026Annual reportSEC
8-K · Current reportFeb 24, 2026Material contractSEC
10-Q · Quarterly reportNov 13, 2025Quarterly reportSEC
8-K · Current reportOct 24, 2025Material contractSEC
UPLOAD · Letter from the SECSep 15, 2025Other filingsSEC
10-Q · Quarterly reportAug 13, 2025Quarterly reportSEC
CORRESP · Letter to the SECJul 22, 2025Other filingsSEC
UPLOAD · Letter from the SECJul 17, 2025Other filingsSEC
10-Q · Quarterly reportMay 14, 2025Quarterly reportSEC
4 · Change in ownershipApr 10, 2025Insider tradeSEC
4 · Change in ownershipApr 7, 2025Insider tradeSEC
4 · Change in ownershipApr 7, 2025Insider tradeSEC
4 · Change in ownershipApr 7, 2025Insider tradeSEC
4 · Change in ownershipApr 7, 2025Insider tradeSEC
10-K · Annual reportMar 28, 2025Annual reportSEC
5 · Annual statement of ownershipFeb 19, 2025Insider tradeSEC
5 · Annual statement of ownershipFeb 19, 2025Insider tradeSEC
10-Q · Quarterly reportNov 12, 2024Quarterly reportSEC
10-Q · Quarterly reportAug 6, 2024Quarterly reportSEC
4 · Change in ownershipMay 16, 2024Insider tradeSEC
4 · Change in ownershipMay 16, 2024Insider tradeSEC
4 · Change in ownershipMay 16, 2024Insider tradeSEC
4 · Change in ownershipMay 16, 2024Insider tradeSEC
4 · Change in ownershipMay 16, 2024Insider tradeSEC
10-Q · Quarterly reportMay 13, 2024Quarterly reportSEC
10-K · Annual reportMar 29, 2024Annual reportSEC
8-K · Current reportDec 14, 2023Material contractSEC
10-Q · Quarterly reportNov 13, 2023Quarterly reportSEC
8-K · Current reportOct 18, 2023Management or board changeSEC
4 · Change in ownershipAug 29, 2023Insider tradeSEC
3 · Initial statement of ownershipAug 29, 2023Insider tradeSEC
8-K · Current reportAug 29, 2023Management or board changeSEC
10-Q · Quarterly reportAug 11, 2023Quarterly reportSEC
8-K · Current reportMay 31, 2023Management or board changeSEC
SC 13D · Big-stake noticeMay 23, 2023Big-stake noticeSEC
SC 13G · Big-stake noticeMay 23, 2023Big-stake noticeSEC
3 · Initial statement of ownershipMay 22, 2023Insider tradeSEC
4 · Change in ownershipMay 17, 2023Insider tradeSEC
3 · Initial statement of ownershipMay 17, 2023Insider tradeSEC
4 · Change in ownershipMay 17, 2023Insider tradeSEC
SC 13G · Big-stake noticeMay 17, 2023Big-stake noticeSEC
10-Q · Quarterly reportMay 15, 2023Quarterly reportSEC
10-K · Annual reportMar 31, 2023Annual reportSEC
3 · Initial statement of ownershipDec 22, 2022Insider tradeSEC
3 · Initial statement of ownershipDec 22, 2022Insider tradeSEC
3 · Initial statement of ownershipDec 22, 2022Insider tradeSEC
3 · Initial statement of ownershipDec 22, 2022Insider tradeSEC
3 · Initial statement of ownershipDec 22, 2022Insider tradeSEC
8-K · Current reportDec 19, 2022Material contractSEC
10-Q · Quarterly reportNov 14, 2022Quarterly reportSEC
8-K · Current reportSep 15, 2022Current reportSEC
10-Q · Quarterly reportAug 12, 2022Quarterly reportSEC
8-K · Current reportJun 3, 2022Management or board changeSEC
10-Q · Quarterly reportMay 13, 2022Quarterly reportSEC
10-K · Annual reportMar 30, 2022Annual reportSEC
8-K · Current reportJan 18, 2022Material contractSEC
10-Q · Quarterly reportNov 12, 2021Quarterly reportSEC
10-Q · Quarterly reportAug 13, 2021Quarterly reportSEC
10-Q · Quarterly reportMay 14, 2021Quarterly reportSEC
10-K · Annual reportMar 26, 2021Annual reportSEC
4 · Change in ownershipJan 19, 2021Insider tradeSEC
8-K · Current reportJan 6, 2021Management or board changeSEC
4 · Change in ownershipDec 28, 2020Insider tradeSEC
4 · Change in ownershipDec 28, 2020Insider tradeSEC
4 · Change in ownershipDec 28, 2020Insider tradeSEC
4 · Change in ownershipDec 28, 2020Insider tradeSEC
4 · Change in ownershipDec 28, 2020Insider tradeSEC
4 · Change in ownershipDec 28, 2020Insider tradeSEC
8-K · Current reportDec 17, 2020Material contractSEC
10-Q · Quarterly reportNov 16, 2020Quarterly reportSEC
8-K · Current reportSep 23, 2020Management or board changeSEC
4 · Change in ownershipSep 21, 2020Insider tradeSEC
4 · Change in ownershipSep 21, 2020Insider tradeSEC
10-Q · Quarterly reportAug 12, 2020Quarterly reportSEC
4 · Change in ownershipJul 20, 2020Insider tradeSEC
8-K · Current reportJun 30, 2020Management or board changeSEC
8-K · Current reportJun 8, 2020Current reportSEC
8-K · Current reportMay 6, 2020Material contractSEC
10-Q · Quarterly reportMay 1, 2020Quarterly reportSEC
8-K · Current reportApr 16, 2020Management or board changeSEC
10-K · Annual reportMar 30, 2020Annual reportSEC
4 · Change in ownershipMar 24, 2020Insider tradeSEC
4 · Change in ownershipMar 24, 2020Insider tradeSEC
4 · Change in ownershipMar 24, 2020Insider tradeSEC
4 · Change in ownershipMar 24, 2020Insider tradeSEC
5 · Annual statement of ownershipFeb 10, 2020Insider tradeSEC
8-K · Current reportJan 3, 2020Management or board changeSEC
4 · Change in ownershipDec 16, 2019Insider tradeSEC
DEF 14CDec 5, 2019Meeting noticeSEC
4 · Change in ownershipDec 2, 2019Insider tradeSEC
10-Q · Quarterly reportNov 7, 2019Quarterly reportSEC
3 · Initial statement of ownershipNov 1, 2019Insider tradeSEC
8-K · Current reportOct 31, 2019Management or board changeSEC
8-K · Current reportAug 27, 2019Material contractSEC
8-K · Current reportAug 20, 2019Current reportSEC
10-Q · Quarterly reportAug 12, 2019Quarterly reportSEC
8-K · Current reportJul 17, 2019Current reportSEC
8-K · Current reportJul 1, 2019Management or board changeSEC
8-K · Current reportJun 19, 2019Current reportSEC
4 · Change in ownershipJun 10, 2019Insider tradeSEC
DEF 14CJun 3, 2019Meeting noticeSEC
PRE 14CMay 24, 2019Meeting noticeSEC
10-Q · Quarterly reportMay 9, 2019Quarterly reportSEC
EFFECT · Notice that a registration is effectiveMay 1, 2019Other filingsSEC
POS AM · Amendment to an effective registrationApr 26, 2019Offer documentSEC
8-K · Current reportApr 15, 2019Current reportSEC
CT ORDERApr 1, 2019Other filingsSEC
10-K · Annual reportMar 7, 2019Annual reportSEC
8-K · Current reportFeb 13, 2019Current reportSEC
4 · Change in ownershipFeb 5, 2019Insider tradeSEC
4 · Change in ownershipFeb 5, 2019Insider tradeSEC
4 · Change in ownershipFeb 5, 2019Insider tradeSEC
4 · Change in ownershipFeb 5, 2019Insider tradeSEC
4 · Change in ownershipJan 24, 2019Insider tradeSEC
DEF 14CJan 8, 2019Meeting noticeSEC
8-K · Current reportDec 31, 2018Material contractSEC
PRE 14CDec 28, 2018Meeting noticeSEC
4 · Change in ownershipDec 26, 2018Insider tradeSEC
4 · Change in ownershipDec 26, 2018Insider tradeSEC
DEF 14CDec 21, 2018Meeting noticeSEC
4 · Change in ownershipDec 19, 2018Insider tradeSEC
SC 13D/A · Big-stake notice, amendedDec 19, 2018Big-stake noticeSEC
8-K · Current reportDec 17, 2018Material contractSEC
10-Q · Quarterly reportNov 14, 2018Quarterly reportSEC
8-K · Current reportNov 5, 2018Current reportSEC
SC 13D/A · Big-stake notice, amendedNov 5, 2018Big-stake noticeSEC
4 · Change in ownershipAug 31, 2018Insider tradeSEC
10-Q · Quarterly reportJul 23, 2018Quarterly reportSEC
8-K · Current reportJul 10, 2018FinancingSEC
4 · Change in ownershipJul 6, 2018Insider tradeSEC
SC 13D/A · Big-stake notice, amendedJul 6, 2018Big-stake noticeSEC
10-Q · Quarterly reportMay 1, 2018Quarterly reportSEC
EFFECT · Notice that a registration is effectiveApr 18, 2018Other filingsSEC
POS AM · Amendment to an effective registrationApr 4, 2018Offer documentSEC
4 · Change in ownershipMar 15, 2018Insider tradeSEC
4 · Change in ownershipMar 15, 2018Insider tradeSEC
4 · Change in ownershipMar 15, 2018Insider tradeSEC
4 · Change in ownershipMar 15, 2018Insider tradeSEC
4 · Change in ownershipMar 15, 2018Insider tradeSEC
4 · Change in ownershipMar 15, 2018Insider tradeSEC
10-K · Annual reportFeb 16, 2018Annual reportSEC
4 · Change in ownershipFeb 12, 2018Insider tradeSEC
4 · Change in ownershipFeb 12, 2018Insider tradeSEC
CT ORDERJan 22, 2018Other filingsSEC
4 · Change in ownershipJan 11, 2018Insider tradeSEC
SC 13D/A · Big-stake notice, amendedJan 11, 2018Big-stake noticeSEC
8-K · Current reportJan 11, 2018Material contractSEC
8-K · Current reportDec 20, 2017Meeting outcomeSEC
DEF 14A · Proxy statementNov 13, 2017Meeting noticeSEC
10-Q · Quarterly reportOct 31, 2017Quarterly reportSEC
8-K · Current reportOct 5, 2017Current reportSEC
10-Q · Quarterly reportJul 31, 2017Quarterly reportSEC
SC 13D/A · Big-stake notice, amendedJul 27, 2017Big-stake noticeSEC
8-K · Current reportJul 27, 2017Current reportSEC
4 · Change in ownershipJul 19, 2017Insider tradeSEC
4 · Change in ownershipJul 19, 2017Insider tradeSEC
4 · Change in ownershipJul 12, 2017Insider tradeSEC
8-K · Current reportMay 30, 2017Current reportSEC
10-Q · Quarterly reportMay 8, 2017Quarterly reportSEC
EFFECT · Notice that a registration is effectiveApr 26, 2017Other filingsSEC
POS AM · Amendment to an effective registrationApr 21, 2017Offer documentSEC
4 · Change in ownershipMar 10, 2017Insider tradeSEC
4 · Change in ownershipMar 10, 2017Insider tradeSEC
4 · Change in ownershipMar 10, 2017Insider tradeSEC
4 · Change in ownershipMar 10, 2017Insider tradeSEC
4 · Change in ownershipMar 10, 2017Insider tradeSEC
10-K · Annual reportFeb 17, 2017Annual reportSEC
8-K · Current reportJan 24, 2017Current reportSEC
3 · Initial statement of ownershipDec 6, 2016Insider tradeSEC
DEF 14CDec 5, 2016Meeting noticeSEC
8-K · Current reportDec 2, 2016Management or board changeSEC
SC 13D/A · Big-stake notice, amendedDec 2, 2016Big-stake noticeSEC
3 · Initial statement of ownershipNov 30, 2016Insider tradeSEC
8-K · Current reportNov 28, 2016Material contractSEC
SC 13D/A · Big-stake notice, amendedNov 28, 2016Big-stake noticeSEC
4 · Change in ownershipNov 15, 2016Insider tradeSEC
SC 13D/A · Big-stake notice, amendedNov 15, 2016Big-stake noticeSEC
8-K · Current reportNov 8, 2016Current reportSEC
SC 13D/A · Big-stake notice, amendedNov 7, 2016Big-stake noticeSEC
4 · Change in ownershipNov 7, 2016Insider tradeSEC
10-Q · Quarterly reportOct 31, 2016Quarterly reportSEC
S-8 · Registration statement for employee plansOct 24, 2016Offer documentSEC
10-Q · Quarterly reportAug 12, 2016Quarterly reportSEC
424B3 · ProspectusJul 26, 2016Offer documentSEC
EFFECT · Notice that a registration is effectiveJul 25, 2016Other filingsSEC
CORRESP · Letter to the SECJul 21, 2016Other filingsSEC

This page holds 200 of 725 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Inhibitor Therapeutics Inc.’s releases

Common shares
174,781,968
Fully diluted
174,781,968

Fully diluted

LineShares
Common shares174,781,968

Share count over time

CountShares
Nov 22, 2026174,781,968

Open Cap table

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Michael Jerman
Other companies: Alaunos Therapeutics, Inc. (Managing Partner of Hollywell Partners · Since at least Jul 15, 2025); Telomir Pharmaceuticals, Inc. (Director · Feb 8, 2024 – Aug 27, 2024 · Past); MIRA Pharmaceuticals, Inc. (Director · Nov 14, 2023 – Mar 25, 2024 · Past)
Director · Since at least Apr 1, 2024
W. Mark Watson
Other companies: Vaxart, Inc. (Lead Independent Director · Since at least Aug 4, 2022); Sykes Enterprises Incorporated (Director · May 22, 2018 – Aug 27, 2021 · Past); BioDelivery Sciences International Inc (Director · Dec 8, 2016 – Mar 22, 2022 · Past)
Director · Aug 14, 2015 – Dec 22, 2020 · Past
James A. McNulty
Other companies: Lunai Bioworks Inc. (Director · Since at least Oct 14, 2024); CV Sciences, Inc. (Director · Feb 5, 2018 – Jun 16, 2020 · Past)
Chief Financial Officer · Since at least Dec 13, 2022
Michelle Yanez
Other companies: Telomir Pharmaceuticals, Inc. (Chief Financial Officer · Jun 18, 2024 – Aug 27, 2024 · Past); MIRA Pharmaceuticals, Inc. (Chief Financial Officer · Aug 2, 2023 – Dec 9, 2024 · Past)
Director · Since at least Dec 13, 2022
Francis E Odonnell Jr
Other companies: BioDelivery Sciences International Inc (Director · Jun 15, 2016 – May 11, 2020 · Past)
Chief Executive Officer, Director · Since at least Jun 6, 2016
Garrison J Hasara
Other companies: Accentia Biopharmaceuticals Inc (Acting Chief Financial Officer · Jan 15, 2011 – Aug 24, 2012 · Past)
CFO and Treasurer · Aug 12, 2013 – Dec 22, 2020 · Past
Niraj Vasisht
Other companies: BioDelivery Sciences International Inc (SVP & Chief Technology Officer · Jan 1, 2016 – Mar 24, 2017 · Past)
CEO · Since at least Dec 13, 2022
Richard Dana Ono
Other companies: Lipocine Inc. (Director · Since at least Jan 6, 2014)
Director · Jun 24, 2014 – Dec 22, 2020 · Past
Samuel P Sears Jr
Other companies: BioDelivery Sciences International Inc (Director · Oct 19, 2011 – Nov 15, 2017 · Past)
Director · Since at least Jan 10, 2006
Daniel O HaydenDirector · Mar 27, 2007 – Mar 27, 2007 · Past
All 27 people
PersonSeat
Debra PeattieDirector · Oct 30, 2019 – Dec 22, 2020 · Past
E Brendan MagrabDirector · Nov 22, 2016 – Feb 3, 2019 · Past
Francis E. O’DonnellFounder/ Executive Officer/ Director · Since at least Nov 5, 2026
Gerald P KruegerDirector · Apr 19, 2006 – May 15, 2006 · Past
James D CauseyDirector · Dec 31, 2007 – Dec 31, 2007 · Past
James H BrennanVP Financial Operations · Dec 15, 2005 – Dec 29, 2008 · Past
Mike JermanCFO · Since at least Nov 4, 2026
Nicholas J VircaPresident and CEO · Aug 12, 2013 – Dec 22, 2020 · Past
Nick HaganCEO of subsidiary · Feb 9, 2007 – Feb 9, 2007 · Past
Richard J FreerChief Executive Officer, Director · Jan 3, 2006 – Apr 12, 2013 · Past
Robert B HarrisPresident · Jan 3, 2006 – Dec 29, 2008 · Past
Robert Daniel MartinDirector · Nov 30, 2016 – Dec 22, 2020 · Past
Ronald E. OsmanChairman of the Board · Since at least May 5, 2023
Samuel SearsManaging Partner, Chairman of the Corporate Department · Since at least Nov 5, 2026
Stefan CrossDirector · Jun 24, 2014 – Dec 19, 2017 · Past
Thomas R ReynoldsExecutive VP · Jan 3, 2006 – Dec 29, 2008 · Past
William X GuoChairman, Director · Sep 12, 2008 – Sep 12, 2008 · Past

Open People

Log in to ask 6ix AI your own questions about Inhibitor Therapeutics Inc.